Earnings, analyst actions and a buyout new peppered health stock headlines on largely flat Thursday after losses earlier in the week.

Biotech company Invitrogen ( IVGN) said Thursday it will buy Applera Corp.'s scientific-instrument company Applied Biosystems ( ABI) in a $6.7 billion cash and stock deal. Invitrogen shares gave up 10.7% to $38.73, while Applied Biosystems climbed 5.3% to $34.16.

Invitrogen is a component of the Nasdaq biotechnology index, ended just above the flat line.

Elsewhere, China Medical ( CMED) rose 17.5% to $39.28. The company said that it earned $15 million, or 53 cents per American depositary share, in the recent quarter. It recorded an adjusted profit of 66 per ADS, vs. 44 cents in the year prior. Revenue increased to $40.6 million. Analysts expected $36.8 million, on average, according to Thomson-Reuters.

Looking ahead, China Medical guided to a profit of $2.87 to $2.96 a share, on revenue in a range of $169.7 million to $175.4 million. Analysts expected $2.55 a share on $161.9 million in revenue, on average.

Meanwhile, Chindex International ( CHDX), an American health-care company that provides services, equipment and products to the Chinese marketplace, sank 29.7% to $14.60. The company said revenue rose 40% to $34.6 million in the quarter ended March 31, but reported a loss of $2.7 million, or 20 cents a share, vs. a profit of $665,000, or 6 cents a share, the year prior. Chindex said the results were impacted by certain non-routine year-end adjustments as well as the interest charge related to the conversion of a JPMorgan convertible bond.

A few analyst actions in the health stocks: Citigroup analyst Lucy Lu downgrade BioMarin ( BMRN) to hold from buy and lowered her price target to $37 from $42, after surveying 26 treatment centers on Kuvan, a drug for the genetic disorder phenylketonuria (PKU), and subsequently lowering sales and profit expectations.

The stock traded down 3.3% to $34.47.

Also, HSBC Securities downgraded Novartis ( NVS) to underweight from neutral and lowered its price target to $49 from $52. The stock was off by just 8 cents, or 0.2%, at $50.35.

In other health stocks, Lehman Brothers downgraded Lifepoint Hospitals ( LPNT) to equal-weight from overweight but the stock was seemingly unaffected, adding 83 cents, or 2.9%, to $29.77.

And Tenet Healthcare ( THC) added 39 cents, or 7.4%, to $5.69 after Lehman Brothers analyst Adam Feinstein upgraded the stock to overweight from equalweight, citing new contracts and potential growth despite industry hardships.

If you liked this article you might like

Stocks Mixed After Working on Railroad

Stocks Mixed After Working on Railroad

Stocks Log a Volatile Win

Stocks Log a Volatile Win

Stocks Get Spooked

Stocks Get Spooked

Dow's Gain: 199.89 as GDP Wows Wall Street

Dow's Gain: 199.89 as GDP Wows Wall Street

Stocks Trip Over Charts; Nasdaq Pummeled

Stocks Trip Over Charts; Nasdaq Pummeled